Don Listwin, Canary Foundation
Mr. Listwin is the Chairman of the GenoLogics board and founder and chairman of Canary Foundation, the United States’ only non-profit organization devoted exclusively to early detection of cancer. A 25-year veteran of the technology industry - he was CEO of Openwave and had been the #2 executive at Cisco Systems – Mr. Listwin walked away from his high profile technology career and launched Canary Foundation as a way to address the imbalance in cancer research. Canary Foundation has assembled a science team that includes some of the world's leading cancer researchers to attack early detection in a new, collaborative approach. Canary Foundation's ultimate goal is to speed development of biomarkers that can detect the presence of cancers at their very earliest stage, when they are most treatable and chances for full recovery are greatest. Mr. Listwin also serves on the boards of Sana Security, Stratos Biosciences, and the Listwin Family Foundation. He is also a member of the Board of Trustees at the Fred Hutchinson Cancer Research Center. A native of Canada, Mr. Listwin holds a B.S. in electrical engineering and an honorary doctorate of law from the University of Saskatchewan.
Joe Timlin, GrowthWorks Capital
Joe Timlin joined GrowthWorks Capital in 2002 focusing on software and information technology investments. Prior to joining GrowthWorks Capital, he worked for four years with BDC's Venture Capital Group focusing on information technology and alternative energy investments. Joe has experience in technical sales and sales management, and has worked as a construction engineer. Joe has a BSc in Civil Engineering from Queen's University and a MBA from UBC. Joe is currently on the Board of Directors of Bycast, Layer-7 Technologies, Make Technologies, ResponseTek Networks, Sutus, Teradici, and QuIC Financial Technologies.
Michael Ball, GenoLogics
Michael has served as CEO at GenoLogics since the Company’s commercial launch of its LIMS solution in 2004. Michael has been instrumental to the success of GenoLogics, securing significant venture capital and building strategic relationships with key partners and customers in the life sciences industry. He brings 25 years of international experience in sales, marketing, and business development with technology companies ranging from start-ups to Fortune 500 firms. Michael spent five years in executive management with Creo Products (acquired by Kodak) as VP Business Development and VP European Sales and Service. During his time at Creo, the business grew from $70 million to $700 million in revenues and it conducted a highly successful IPO. Previously, he spent seven years at Digital Equipment Corp. (now part of HP) in sales and marketing. Michael serves on the Board of the Canary Foundation, the only non-profit organization in the United States that is devoted exclusively to the early detection of cancer.
Steve has been active in the development and financing of emerging technology companies for more than 20 years. He co-founded Yaletown Venture Partners in 2001 and was active in building the firm and its portfolio until 2010. Today he is an Executive Limited Partner investor in Yaletown-managed funds alongside other technology industry executives and entrepreneurs, and major Canadian and US institutional investors. Prior to starting Yaletown, Steve established and built TD Bank’s technology financing group on the west coast of Canada, was an executive in the technology industry group of PwC, and began his career as a software engineer with Accenture. Steve is active on the boards of several venture-backed companies, one Crown Corporation, two non-profit foundations, serves as Vice President of the board of directors for Canada’s Venture Capital & Private Equity Association (CVCA), and is on the editorial boards of Business in Vancouver newspaper and Canadian Private Capital magazine. He is a graduate of the University of British Columbia and British Columbia Institute of Technology, magna cum laude.
Tristan Orpin, Senior Vice President and Chief Commercial Officer, Illumina Inc.
Tristan Orpin joined Illumina in December 2002 in the role of vice president of worldwide sales, and in January 2007 was promoted to senior vice president of commercial operations. Before joining Illumina, Tristan held positions at Sequenom including vice president of sales and marketing from August 2001 to November 2002 and director of sales and marketing from September 1999 to August 2001. For more than a decade prior Tristan served in several senior sales and marketing positions at Bio-Rad Laboratories. Tristan earned a B.S. in genetics and biochemistry with first class honors from the University of Melbourne.